O Rodriguez-Gomez, A Sanabria, A Perez-Cordon, D Sanchez-Ruiz, C Abdelnour, S Valero, I Hernandez, M Rosende-Roca, A Mauleon, L Vargas, M Alegret, A Espinosa, G Ortega, M Guitart, A Gailhajanet, O Sotolongo-Grau, S Moreno-Grau, S Ruiz, M Tarragona, J Serra, E Martin, E Peleja, F Lomeña, F Campos, A Vivas, M Gomez-Chiari, M A Tejero, J Giménez, P Pesini, M Sarasa, G Martinez, A Ruiz, L Tarraga, M Boada
BACKGROUND: Long-term longitudinal studies with multimodal biomarkers are needed to delve into the knowledge of preclinical AD. Subjective cognitive decline has been proposed as a risk factor for the development of cognitive impairment. Thus, including individuals with SCD in observational studies may be a cost-effective strategy to increase the prevalence of preclinical AD in the sample. OBJECTIVES: To describe the rationale, research protocols and baseline characteristics of participants in the Fundació ACE Healthy Brain Initiative (FACEHBI)...
2017: Journal of Prevention of Alzheimer's Disease